CPL500036
CPL500036 is an orally active, blood-brain barrier permeable phosphodiesterase 10A (PDE10A) inhibitor with IC50 values of 1 nM (Reference 1) and 35 nM (Reference 2). CPL500036 acts as a negative allosteric modulator of the M2 muscarinic receptor with an IC50 of 9.2 μM. CPL500036 alters cyclic nucleotide levels in basal ganglia circuits, inhibits the hydrolysis of cAMP and cGMP, and suppresses hERG potassium channel tail currents. CPL500036 induces catalepsy in rats and reverses injury-induced contralateral forelimb use impairment. CPL500036 can be used in research related to schizophrenia, Parkinson's disease, and levodopa-induced dyskinesia.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1829530-11-1
- Fòrmula: C19H15N7
- Peso molecular:341.37
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
PDE10A 1 nM (IC50) |
PDE10A 35 nM (IC50) |
CPL500036 (0.1-10 μM; 5 min) inhibits hERG tail current in hERG-HEK-293 transfected cells with an IC25 of 3.2 μM[1].
CPL500036 (0.0457-100 μM; 14 days) does not affect key cardiac spheroid health parameters up to 100 μM, but impairs DNA structure with an IC50 of 37.4 μM in human pluripotent cell-derived 3D cardiac spheroids[1].
CPL500036 (8 nM-60 μM; 72 h) is not cytotoxic at concentrations up to 60 μM in NCI-H1299, HepG2, and SH-SY5Y cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CPL500036 (0.1-0.3 mg/kg; p.o.; single acute administration combined with Levodopa (HY-N0304)/Benserazide (HY-121275) for 16 consecutive days) dose-dependently improves sensorimotor deficits in 6-hydroxydopamine-lesioned rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, ~300 g)[1]
-
Dosage:0.15 mg/kg; 0.3 mg/kg; 0.6 mg/kg; 2 mg/kg
-
Administration:p.o.; single dose
-
Result:Did not induce catalepsy at 0.15 mg/kg.
Induced a low cataleptogenic effect only at 210 min and 240 min post-administration at 0.3 mg/kg.
Induced catalepsy from 120 min to 240 min post-administration at 0.6 mg/kg, with effect less than positive control haloperidol.
Produced a strong cataleptogenic effect comparable to haloperidol at 2 mg/kg.
Confirmed minimum effective dose (MED) for catalepsy as 0.6 mg/kg via AUC data.
-
Animal Model:Wistar Han (male, initial body weight 270-300 g, unilateral medial forebrain bundle lesion with 6-hydroxydopamine)[2]
-
Dosage:0.1 mg/kg (acute single dose; chronic daily combined with L-DOPA/benserazide); 0.3 mg/kg (acute single dose; chronic daily combined with L-DOPA/benserazide)
-
Administration:p.o.; single acute dose; daily for 16 days (combined with L-DOPA/benserazide)
-
Result:Dose-dependently reversed impaired forelimb use in the stepping test after acute administration.
Completely restored forelimb use symmetry in the cylinder test during the second post-dose testing session at 0.3 mg/kg acute dose.
Did not affect vibrissae test deficits or lesion-induced catalepsy at either acute dose.
Significantly improved impaired forelimb performance in the vibrissae test when combined acutely with L-DOPA at 0.1 mg/kg.
Reduced L-DOPA-induced contralateral rotations when combined acutely with L-DOPA at 0.3 mg/kg.
Completely reversed forelimb asymmetry in the vibrissae test after chronic combined treatment at 0.3 mg/kg.
Did not alter L-DOPA's antiparkinsonian effects in the stepping, catalepsy, or rotation tests at either chronic dose.
Significantly improved impaired forelimb use in the stepping test in the OFF phase post-chronic treatment at 0.3 mg/kg combined with L-DOPA compared to lesioned rats.
Chemical Information
-
No. CAS 1829530-11-1
-
Peso molecular 341.37
-
Fòrmula C19H15N7
-
SMILES
CC1=NC=C(C)N2N=C(C3=NC4=NC(C5=CC=CC=C5)=CN4C=C3)N=C21
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Matloka M, et al. A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. Front Pharmacol. 2022;13:999685. Published 2022 Nov 9. [Content Brief]
[2]. Lenda T, et al. Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease. Eur J Pharmacol. 2021;910:174460. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CPL500036 Related Classifications
HY-182638 Related Classifications
Powered by Bioz